Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Progressive Corp (PGR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Progressive Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Progressive Corp trades at $231.86 (market cap $134.33B). The key difference: Progressive Corp is far larger — about 3.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Progressive Corp pays a 6.02% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PGR | |
|---|---|---|
Market Cap | $39.89B | $134.33B |
Sector | Health | Financials |
52-Week High | $491.22 | $252.68 |
52-Week Low | $278.09 | $190.40 |
Enterprise Value | $38.15B | $142.55B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Progressive (PGR) trades at $230.72, up 0.52% on the day, with a bullish technical outlook indicated by moving averages and strong support at $228. The stock shows robust fundamentals with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income surging to $11.3B. Recent earnings beats and a 36% jump in May 2026 net income highlight operational strength. The company maintains a solid net income margin of 12.93% and an impressive ROE of 37.9%.
The outlook for PGR is positive, supported by consistent earnings outperformance and analyst consensus pointing to upside with a $239.75 price target. Key risks include competitive pressures in the insurance sector and potential macroeconomic headwinds affecting consumer spending. Institutional sentiment is mixed but leans bullish, with 39% of analysts rating it a buy. The stock presents a compelling opportunity for growth investors seeking exposure to a financially healthy insurer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
